Biogenerics | Generic Pharmaceutical Association

Biogenerics

GPhA Acclaims Hatch-Waxman as Model for Savings; Urges Shortened Exclusivity Period for Biogenerics

Press Release | November 7, 2011

GPhA Response to FDA Request for Comment on the Implementation of the Abbreviated Biogeneric Pathway

GPhA Response to FDA Request for Comment on the Implementation of the Abbreviated Biogeneric Pathway

Testimony of Rasmus Rojkjaer, M.D., Ph.D, Mylan Inc. on behalf of GPhA at the FDA Meeting on Biogenerics

GPhA Tells FDA that Science-Based Biogeneric Approval Process Is Needed To Assure Lower Costs for Patients

Press Release | November 3, 2010

GPhA/FDA Fall Tech Conference Highlights Coming Biosimilar Market

Press Release | October 20, 2010

White House Ignores Savings from Increasing Access to Generic Medicine

Press Release | March 3, 2010

GAO Report on Lack of Competition for Medicare Biotech Drugs Again Underscores Need for Congress to Act, GPhA Says

Press Release | March 1, 2010

GPhA Urges the White House and Congress to Heed Message of CCPM Health Care Reform Ad Campaign

Press Release | December 17, 2009

Senate HCR Bill Gratuitously Extends Biologic Monopolies: Lifts Brand Profits to New Heights At Consumer Expense

Press Release | November 19, 2009